Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of TV-46000 (risperidone extended-release injectable suspension) for maintenance treatment of schizophrenia
2019-000063-24Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of risperidone in schizophrenia, sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Primary safety endpoint. Started May 2019; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2019-000063-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000063-24.